The Economic Burden of Viral hepatitis C infection at various stages of the disease in District Mardan, Pakistan: Economic Burden of Viral hepatitis C Infection

Sajjad Khan; Misbah Nosheen

doi:10.54393/pbmj.v5i5.482

Authors

Sajjad Khan Department of Economics Hazara University, Mansehra, Khyber Pakhtunkhwa, Pakistan
Misbah Nosheen Department of Economics Hazara University, Mansehra, Khyber Pakhtunkhwa, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i5.482

Keywords:

Economic Burden, HCV, Cirrhosis, District Mardan

Abstract

Hepatitis C is a blood-borne, infectious disease caused by the Hepatitis C virus (HCV). It attacks hepatic cells, causing infection and inflammation in the liver, eventually leading to cirrhosis and hepatocellular cancer (HCC). Globally, around 200M people carry HCV with mortality rate of 350,000 due to chronic complications of the liver triggered by HCV. Objective: To assess the overall annual cost borne by chronic HCV patients at various stages of the disease in District Mardan, Pakistan. Methods: Out of total 160 patients, 135, 19 and 6 patients had non-cirrhotic, compensated cirrhosis, decompensated cirrhosis and other complications respectively, Data were obtained from these identified patients’ trough well designed questions based on their social and economic burden in 2019. Descriptive and inferential statistical techniques were applied to estimate the direct and indirect medical costs of HCV in District Mardan. Results: This research discovered a significant link between direct and indirect costs and various phases of viral hepatitis C. The per patient annual indirect costs non-medical costs at different stage of HCV infection was found Rs. 10000 (66.57 $), Rs. 25700 (171.10 $) and Rs. 83200 (553.92 $) for non- cirrhotic, compensated cirrhosis and decompensated cirrhosis patients where non-medical costs were estimated Rs. 2000 (13.31 $), Rs. 3235 (66.57 $), and Rs. 7540 (50.19 $), for non- cirrhotic, compensated cirrhosis and decompensated cirrhosis patients and their average were estimated as Rs.51533 (343.09 $), and 4258.33 (28.35. whereas The estimated per patient direct cost for non-cirrhotic, compensated cirrhosis and decompensated cirrhosis are Rs.51060 (339.94 $), 108650 (723.36 $) and 224370(1493.80 $). Conclusions: It was concluded that indirect medical costs grew up with the progression of disease as productivity loss due to absenteeism increases and traveling expenses increases with increased in number of hospital visits.

References

Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003 Nov;9(11):S10-3. doi: 10.1053/jlts.2003.50244.

Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. Hepat Mon. 2008;8(3):165–9.

Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. Sci J Med Council Islam Republic Iran. 1997;15:183–200.

World Health Organization. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2018 Jun 28.

Regev A, Schiff ER. Clinical features of hepatitis. Viral Hepatitis. 3rd ed. Malden, MA: Blackwell Publishing. 2005 Jul 12:32-49.

Kalboussi H, Kacem I, Aroui H, El Maalel O, Maoua M, Brahem A et al. Impact of Allergic Contact Dermatitis on the Quality of Life and Work Productivity. Dermatol Res Pract. 2019 Mar 3;2019:3797536. doi: 10.1155/2019/3797536.

Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA. Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis. J Occup Environ Med. 2013 Mar;55(3):240-4. doi: 10.1097/JOM.0b013e318282d310.

Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol. 2016 Oct;65(1 Suppl):S109-S119. doi: 10.1016/j.jhep.2016.07.005.

Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K et al. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int. 2019 Oct;39(10):1837-1844. doi: 10.1111/liv.14171.

DiBonaventura Md, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14(2):253–261. doi:10.3111/13696998.2011.566294.

Sahakyan Y, Wong WW, Yi Q, Thein HH, Tomlinson GA, Krahn MD. Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up. J Viral Hepat. 2020 Mar;27(3):235-242. doi: 10.1111/jvh.13226.

Saffar MJ, Abedian O, Ajami A, Abedian F, Mirabi AM, Khalilian AR et al. Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review. Hepatitis monthly. 2012 May;12(5):326. doi: 10.5812/hepatmon.6035.

Kavosi Z, Zare F, Jafari A, Fattahi MR. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Middle East J Dig Dis. 2014 Jul;6(3):156-61.

Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran. Hepat Mon. 2016 Mar 5;16(4):e32654. doi: 10.5812/hepatmon.32654.

Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2009 Nov-Dec;12 Suppl 3:S89-92. doi: 10.1111/j.1524-4733.2009.00636.x

Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007 Dec;16(4):403-6.

Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Ann Acad Med Singap. 1980 Apr;9(2):144-8.

Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg. 1993 Oct;96(5):277-87.

Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30. Lancet Glob Health. 2019 Sep;7(9):e1180-e1188. doi: 10.1016/S2214-109X(19)30272-4.